Summary

Overview
Global Cocaine Intoxication Drugs Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Cocaine intoxication is a condition in the person not only high from using the drug but also have body-wide symptoms that can make the person ill and impaired. Cocaine intoxication has been described as a “rush,” including feelings of elation, clarity, well-being, energy, and confidence. Symptoms such as paranoia, intensified sounds and light sensitivity may also occur, as well as increased heart rate, blood pressure, and pupil dilation.
The pattern in which cocaine is abused is in bouts or binge-crash cycles, where doses are repeatedly administered with short inter-dose intervals (5–30 min). Once cocaine use is initiated, the probability is high that more cocaine will be used shortly after that. After the termination of a bout of cocaine use, there may be a period described as a “crash,” characterised by anxiety, irritability, and depression.
Market Dynamics: Drivers and Restraints
Rise in awareness regarding the overuse of cocaine
Awareness campaigns can educate the public, especially young people, about the risks and consequences of cocaine use. Prevention programs in schools, communities, and workplaces can emphasize the dangers of drug abuse and promote healthy alternatives.
For instance, in October 2021, the Centers for Disease Control and Prevention (CDC) launched four complementary education campaigns intended to reach young adults ages 18 to 34 years. The campaigns provide information about the prevalence and dangers of fentanyl, the risks and consequences of mixing drugs, the life-saving power of naloxone, and the importance of reducing stigma around drug use to support treatment and recovery.
CDC spoke directly with young adults who reported using drugs, as well as peer recovery professionals, to develop the campaigns. Each campaign includes new resources on all four topics to help people make informed decisions, get the help they need, and ultimately reduce the rise in drug overdoses and overdose deaths.
As more effective treatments become available, patients with Cocaine Intoxication may experience better health outcomes and quality of life. This could increase demand for management options and further drive market growth.
Furthermore, the cocaine intoxication drugs market is also driven by various other factors like ongoing research and development, which is leading to an increased potential for new and improved treatment options to become available for patients with Cocaine Intoxication and others.
Market Dynamics: Restraint
The market is projected to be significantly affected by challenging factors such as limited availability and high cost of advanced cocaine intoxication treatment options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth.
Segment Analysis
The global cocaine intoxication drugs market is segmented based on drug class, route of administration, distribution channel and region.
The diazepam from the drug class segment accounted for approximately 45.5% of the cocaine intoxication drugs market share
The diazepam from the drug class segment accounted for approximately 45.5% and is expected to dominate during the forecast period. Diazepam appears to be an antidote against this toxicity, suggesting a useful potential strategy for dealing with coca tropine-related hospital emergencies. In the context of pharmacotherapeutic intervention in cocaine toxicity, benzodiazepines such as diazepam are recommended to reduce the central nervous system effects of the drug and to control clinically significant tachycardia and hypertension.
However, it is important to note that some patients who abuse cocaine may have enhanced sensitivity to benzodiazepines, and close monitoring of vital signs is recommended when using vasoactive and antihypertensive medications.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors like advancements in research and developments, FDA approvals, advanced healthcare infrastructure and others that help this region to have the highest market share during the forecast period.
For instance, in July 2022, The New York-based company announced a mid-stage study for major depressive disorder (MDD), which followed the June disclosure of a planned Phase II study for a cocaine intoxication therapy. Plans are in the works to conduct a Phase II study of experimental extended-release (ER) treatment TNX-601 ER, or tianeptine oxalate extended-release, as a potential treatment for MDD. TNX-601 ER sets itself apart from the usual selective serotonin reuptake inhibitor (SSRI) treatment regimens with a formulation unseen in FDA-approved drugs.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a limited impact on cocaine intoxication, but it has led to an increase in drug use disorders and the use of synthetic cannabinoids. The pandemic has also affected drug markets, with some countries experiencing an increase in drug trafficking and cultivation.
Market Segmentation
By Drug Class
• Diazepam
• Morphine
• Phentolamine
• Lorazepam
• Verapamil
By Route of Administration
• Intravenous
• Nasal
• Oral
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Tonix Pharmaceutical, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Pfizer Inc, Novartis AG, Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc, Sun Pharmaceuticals Industries Ltd, Advanz Pharmaceuticals, AdvaCare Pharma and among others.
Key Developments
 In June 2022, Tonix Pharmaceuticals Holding Corp, a clinical-stage biopharmaceutical company, stated the design of a new Phase 2 clinical trial of TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) for the treatment of cocaine intoxication. This new protocol has the potential to serve as a pivotal trial.
TNX-1300 is a recombinant enzyme that efficiently degrades and metabolizes cocaine in cocaine users, as demonstrated in a prior Phase 2a randomized, double-blind, placebo-controlled clinical study, providing support for the use of TNX-1300 as a treatment for cocaine intoxication.
Why Purchase the Report?
• To visualize the global cocaine intoxication drugs market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of cocaine intoxication drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global cocaine intoxication drugs market report would provide approximately 77 tables, 79 figures and 187 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the awareness regarding the overuse of cocaine
4.1.1.2. Rise in the research and development
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Diazepam*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Morphine
7.4. Phentolamine
7.5. Lorazepam
7.6. Verapamil
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Intravenous*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Nasal
8.4. Oral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Tonix Pharmaceutical*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GlaxoSmithKline Plc
12.3. Bristol Myers Squibb Company
12.4. Pfizer Inc
12.5. Novartis AG
12.6. Teva Pharmaceuticals Ltd
12.7. Zydus Pharmaceuticals, Inc
12.8. Sun Pharmaceuticals Industries Ltd
12.9. Advanz Pharmaceuticals
12.10. AdvaCare Pharma
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us